Perrigo (PRGO +1.6%) files an Abbreviated New Drug Application with the FDA for albuterol sulfate HFA inhalation aerosol, a generic version of Teva Pharmaceutical's (TEVA +1%) ProAir HFA. The filing involves contributions from both PRGO and Catalent Pharma Solutions, who partnered on the development. TEVA claims the application violates its patent on the drug, and yesterday it filed suit against both companies in U.S. District Court alleging patent infringement.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at CNBC.com (Dec 30, 2014)
at Benzinga.com (Dec 23, 2014)
at CNBC.com (Nov 6, 2014)
at MarketWatch.com (Sep 29, 2014)
at CNBC.com (Aug 29, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs